CA3129411A1 - Beta-hydroxybutyrate mixed salt-acid compositions and methods of use - Google Patents
Beta-hydroxybutyrate mixed salt-acid compositions and methods of use Download PDFInfo
- Publication number
- CA3129411A1 CA3129411A1 CA3129411A CA3129411A CA3129411A1 CA 3129411 A1 CA3129411 A1 CA 3129411A1 CA 3129411 A CA3129411 A CA 3129411A CA 3129411 A CA3129411 A CA 3129411A CA 3129411 A1 CA3129411 A1 CA 3129411A1
- Authority
- CA
- Canada
- Prior art keywords
- beta
- hydroxybutyrate
- composition
- acid
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title claims abstract description 283
- 239000000203 mixture Substances 0.000 title claims abstract description 159
- 239000002253 acid Substances 0.000 title abstract description 83
- 238000000034 method Methods 0.000 title description 6
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 36
- 239000011777 magnesium Substances 0.000 claims abstract description 36
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 28
- 239000011575 calcium Substances 0.000 claims abstract description 28
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 26
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 25
- 239000011734 sodium Substances 0.000 claims abstract description 25
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 22
- 239000011591 potassium Substances 0.000 claims abstract description 22
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 14
- 150000002576 ketones Chemical class 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 15
- OXUQOKIBNYSTGF-UHFFFAOYSA-L calcium;3-hydroxybutanoate Chemical compound [Ca+2].CC(O)CC([O-])=O.CC(O)CC([O-])=O OXUQOKIBNYSTGF-UHFFFAOYSA-L 0.000 claims description 12
- CINYGFCEISABSR-UHFFFAOYSA-M potassium;3-hydroxybutanoate Chemical compound [K+].CC(O)CC([O-])=O CINYGFCEISABSR-UHFFFAOYSA-M 0.000 claims description 12
- NBPUSGBJDWCHKC-UHFFFAOYSA-M sodium 3-hydroxybutyrate Chemical compound [Na+].CC(O)CC([O-])=O NBPUSGBJDWCHKC-UHFFFAOYSA-M 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 235000020509 fortified beverage Nutrition 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 230000001777 nootropic effect Effects 0.000 claims description 4
- 235000010603 pastilles Nutrition 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000020650 eye health related herbal supplements Nutrition 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 6
- 235000021554 flavoured beverage Nutrition 0.000 claims 4
- 235000019520 non-alcoholic beverage Nutrition 0.000 claims 4
- 230000002361 ketogenic effect Effects 0.000 abstract description 56
- -1 transition metal cations Chemical class 0.000 abstract description 44
- 208000007976 Ketosis Diseases 0.000 abstract description 42
- 230000004140 ketosis Effects 0.000 abstract description 42
- 239000003792 electrolyte Substances 0.000 abstract description 32
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 18
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract description 18
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 11
- 150000004668 long chain fatty acids Chemical class 0.000 abstract description 10
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract description 10
- 235000005282 vitamin D3 Nutrition 0.000 abstract description 10
- 239000011647 vitamin D3 Substances 0.000 abstract description 10
- 229940021056 vitamin d3 Drugs 0.000 abstract description 10
- 229910052742 iron Inorganic materials 0.000 abstract description 9
- 230000001627 detrimental effect Effects 0.000 abstract description 8
- 230000008821 health effect Effects 0.000 abstract description 8
- 125000002091 cationic group Chemical group 0.000 abstract description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 6
- 229910052723 transition metal Inorganic materials 0.000 abstract description 6
- 239000011701 zinc Substances 0.000 abstract description 6
- 229910052725 zinc Inorganic materials 0.000 abstract description 6
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 239000000061 acid fraction Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 description 38
- 150000001768 cations Chemical class 0.000 description 23
- 239000007788 liquid Substances 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 206010014418 Electrolyte imbalance Diseases 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229960002446 octanoic acid Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000016804 zinc Nutrition 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 235000020887 ketogenic diet Nutrition 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000002207 metabolite Chemical class 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 235000021074 carbohydrate intake Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000252254 Catostomidae Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical group CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000001844 chromium Chemical class 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 150000002696 manganese Chemical class 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002664 nootropic agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 150000003342 selenium Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- QGDOQULISIQFHQ-UHFFFAOYSA-N 1,3,7,9-tetramethyluric acid Chemical compound CN1C(=O)N(C)C(=O)C2=C1N(C)C(=O)N2C QGDOQULISIQFHQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000020197 coconut milk Nutrition 0.000 description 1
- 230000004633 cognitive health Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002410 histidine derivatives Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002519 isoleucine derivatives Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
- 235000007635 levomefolic acid Nutrition 0.000 description 1
- 239000011578 levomefolic acid Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZVQXCXPGLSBNCX-UHFFFAOYSA-N methylliberine Chemical compound O=C1N(C)C(OC)=NC2=C1N(C)C(=O)N2C ZVQXCXPGLSBNCX-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 150000002751 molybdenum Chemical class 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ketogenic compositions including a beta-hydroxybutyrate mixed salt-acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The beta-hydroxybutyrate mixed salt-acid is formulated to provide a biologically balanced set of cationic electrolytes and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and at least two beta-hydroxybutyrate salts selected from sodium, potassium, calcium, and magnesium. The beta-hydroxybutyric acid fraction of the mixed salt-acid composition is more rapidly absorbed and utilized, can improve taste, and can provide a lower pH composition without having to acid citric or other edible acid. The beta-hydroxybutyrate composition may include transition metal cations (e.g., zinc or iron), one or more beta-hydroxybutyrate-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, and excipients.
Description
BETA-HYDROXYBUTYRATE MIXED SALT-ACID
COMPOSITIONS AND METHODS OF USE
BACKGROUND
[0001] Disclosed herein are mixed beta-hydroxybutyrate salt-acid compositions and methods for producing elevated blood levels of ketone bodies in a subject.
COMPOSITIONS AND METHODS OF USE
BACKGROUND
[0001] Disclosed herein are mixed beta-hydroxybutyrate salt-acid compositions and methods for producing elevated blood levels of ketone bodies in a subject.
[0002] In periods of fasting, extreme exercise, and/or low carbohydrate consumption, glucose and glycogen stores in the body are rapidly used and can become quickly depleted.
Failure to replenish glucose stores as they become depleted causes the body to metabolically shift to the creation of ketone bodies for energy ("ketosis"). Ketone bodies can be used by almost all cells of the body as a replacement fuel to satisfy the body's energy needs, including the needs of the brain and heart. During a prolonged fast, for example, blood ketone levels will increase to as high as 2 or 3 mmol/L or more. It is conventionally understood that when blood ketones rise above 0.5 mmol/L, the heart, brain and peripheral tissues are using ketone bodies (beta-hydroxybutyrate and acetoacetate) as the primary fuel source. This condition is referred to as ketosis. At blood levels between 1.0 mmol/L and 3.0 mmol/L the condition is called "nutritional ketosis."
Failure to replenish glucose stores as they become depleted causes the body to metabolically shift to the creation of ketone bodies for energy ("ketosis"). Ketone bodies can be used by almost all cells of the body as a replacement fuel to satisfy the body's energy needs, including the needs of the brain and heart. During a prolonged fast, for example, blood ketone levels will increase to as high as 2 or 3 mmol/L or more. It is conventionally understood that when blood ketones rise above 0.5 mmol/L, the heart, brain and peripheral tissues are using ketone bodies (beta-hydroxybutyrate and acetoacetate) as the primary fuel source. This condition is referred to as ketosis. At blood levels between 1.0 mmol/L and 3.0 mmol/L the condition is called "nutritional ketosis."
[0003] Upon transitioning into ketosis, during ketogenic metabolism in the liver, the body uses dietary and bodily fats as its primary energy source. During ketosis, one can lose body fat by controlling dietary fat intake and lowering carbohydrate intake to sustain ketosis.
While in ketosis, the body is in ketogenisis and burning fat as primary fuel.
The body cleaves fats into fatty acids and glycerol and transforms the fatty acids into acetyl-CoA molecules, which are then eventually transformed through ketogenisis into the water soluble ketone bodies beta-hydroxybutyrate, acetoacetate, and acetone in the liver. Beta-hydroxybutyrate and acetoacetate are used by the body for energy while acetone is removed and expelled as a by-product of ketogenesis.
While in ketosis, the body is in ketogenisis and burning fat as primary fuel.
The body cleaves fats into fatty acids and glycerol and transforms the fatty acids into acetyl-CoA molecules, which are then eventually transformed through ketogenisis into the water soluble ketone bodies beta-hydroxybutyrate, acetoacetate, and acetone in the liver. Beta-hydroxybutyrate and acetoacetate are used by the body for energy while acetone is removed and expelled as a by-product of ketogenesis.
[0004] The metabolism of ketone bodies is associated with several beneficial effects, including anticonvulsant effects, enhanced brain metabolism, neuroprotection, muscle sparing properties, and improved cognitive and physical performance. Science-based improvements in efficiency of cellular metabolism, managed through ketone supplementation, can have beneficial impacts on physical, cognitive health, and psychological health, and a long-term impact on health with respect to common avoidable diseases such as obesity, cardiovascular disease, neurodegenerative diseases, diabetes, and cancer.
[0005] Despite the many health advantages to pursuing a ketogenic diet or lifestyle and maintaining a state of nutritional ketosis, there remain significant barriers to pursuing and maintaining a ketogenic state. One of these is difficulty of transitioning into a ketogenic state. The fastest endogenous way to enter ketosis through depletion of glucose stores in the body is through fasting combined with exercise. This is physically and emotionally demanding and is extremely challenging even for the most motivated and disciplined.
[0006] Additionally, transition into ketosis is often accompanied by hypoglycemia, which can cause lethargy and light-headedness, resulting in an uncomfortable physiological and mental state commonly referred to as "low-carb flu." In addition, many people experience a down regulation in metabolism as the body goes into "energy-saving" mode.
Some suggest in these transitory symptoms may last as long as 2-3 weeks. During this transition period, if any meal or snack consisting of carbohydrates over the restrictive amount is consumed, there is an immediate termination of ketogenisis and the body exits from a state of ketosis and shifts back to glucose utilization as its primary fuel. The transition into ketosis must then begin anew.
Some suggest in these transitory symptoms may last as long as 2-3 weeks. During this transition period, if any meal or snack consisting of carbohydrates over the restrictive amount is consumed, there is an immediate termination of ketogenisis and the body exits from a state of ketosis and shifts back to glucose utilization as its primary fuel. The transition into ketosis must then begin anew.
[0007] If a subject is successful in establishing ketosis, sustaining ketosis is as or more difficult due to the need to maintain a rigid dietary ratio of carbohydrates and protein to fats.
It is further complicated by disruption of normal electrolyte balance, which often occurs when transitioning into and maintaining a ketogenic state. The depletion and lowering of glycogen stores in the liver and muscles lessens the ability of the body to retain water, leading to more frequent urination, and accordingly, a greater loss of electrolytes. Further, the drop in insulin levels caused by ketosis effects the rate at which certain electrolytes are extracted by the kidneys, additionally lowering electrolyte levels in the body.
It is further complicated by disruption of normal electrolyte balance, which often occurs when transitioning into and maintaining a ketogenic state. The depletion and lowering of glycogen stores in the liver and muscles lessens the ability of the body to retain water, leading to more frequent urination, and accordingly, a greater loss of electrolytes. Further, the drop in insulin levels caused by ketosis effects the rate at which certain electrolytes are extracted by the kidneys, additionally lowering electrolyte levels in the body.
[0008] Electrolyte imbalances can lead to fatigue, muscle cramping, headaches, dizziness, depression, constipation, skin problems, muscle weakness, and irritability, exacerbating other detrimental mental and physiological effects often associated with entering and maintaining a ketogenic state, thus further increasing the difficulty of promoting and/or sustaining ketosis. In more extreme cases, electrolyte imbalances can lead to serious health problems, such as heart palpitations, respiratory depression, involuntary muscle spasms, and cardiac arrhythmia.
BRIEF SUMMARY
BRIEF SUMMARY
[0009] Disclosed herein are ketogenic compositions containing beta-hydroxybutyrate mixed salt-acid compositions formulated for inducing and/or sustaining ketosis in a subject while simultaneously promoting or maintaining a beneficial electrolytic balance. For example, the ketogenic compositions may function to induce and/or sustain ketosis in a subject without delivering too much total electrolytes to the body, or too much of a particular electrolyte that may be unhealthy, such as excessive sodium, potassium, magnesium and/or calcium (i.e., so as to not exceed the RDA for a particular electrolyte or only exceed it by a predetermined amount). This allows the ketogenic compositions to induce or sustain ketosis while simultaneously limiting, preventing, or improving electrolyte imbalance in the subject.
[0010] In some embodiments, beta-hydroxybutyrate mixed salt-acid compositions for promoting and/or sustaining ketosis in a subject include a beta-hydroxybutyrate mixed salt formed from a plurality of different cations and a quantity of free beta-hydroxybutyric acid.
The cations can be selected from alkali metals, alkaline earth metals, transition metals, amines, and amino acids. Using a combination of cations and an amount of free beta-hydroxybutyric acid permits higher dosing of beta-hydroxybutyrate while maintaining or promoting electrolyte balance and/or without causing electrolyte imbalances or overload.
The cations can be selected from alkali metals, alkaline earth metals, transition metals, amines, and amino acids. Using a combination of cations and an amount of free beta-hydroxybutyric acid permits higher dosing of beta-hydroxybutyrate while maintaining or promoting electrolyte balance and/or without causing electrolyte imbalances or overload.
[0011] In some embodiments, a beta-hydroxybutyrate mixed salt-acid composition for promoting and/or sustaining ketosis in a subject includes a plurality of beta-hydroxybutyrate salts formulated from a plurality of cations. In some cases, anions other than beta-hydroxybutyrate can be omitted from the mixed beta-hydroxybutyrate salt-acid compositions. The cations are formulated to provide a biologically balanced set of cationic electrolytes upon administration to the subject. The mixed salt-acid composition can include at least two of lithium beta-hydroxybutyrate salt, potassium beta-hydroxybutyrate salt, sodium beta-hydroxybutyrate salt (e.g., in an amount, by weight, that is no greater than an amount, by weight, of potassium beta-hydroxybutyrate salt), magnesium beta-hydroxybutyrate salt, and calcium beta-hydroxybutyrate salt (e.g., in an amount, by weight, that is no greater than an amount, by weight, of magnesium beta-hydroxybutyrate salt).
[0012] Some embodiments include one or more transition metal salts, including but limited to beta-hydroxybutyrate salts, such as zinc salts, iron salts, copper salts, manganese salts, and chromium salts. Other beta-hydroxybutyrate and non-beta-hydroxybutyrate salts include selenium salts and amino acid salts.
[0013] By limiting the total quantity of a single electrolyte salt in the ketogenic composition, it is possible to substantially increase the total quantity of beta-hydroxybutyrate delivered to the body without delivering an excessive or unhealthy quantity of the single electrolyte.
Using a plurality of beta-hydroxybutyrate salts in combination with free beta-hydroxybutyric acid helps maintain proper electrolyte balance.
Using a plurality of beta-hydroxybutyrate salts in combination with free beta-hydroxybutyric acid helps maintain proper electrolyte balance.
[0014] In some embodiments, a ketogenic composition is useful as a weight loss supplement, as a treatment for high blood glucose or type II diabetes, as a brain tonic, athletic performance enhancer, as a preventative against metabolic dysfunction, mitochondrial defect, insulin resistance, as an adjunct to a ketogenic diet, as an anti-aging supplement, and for other uses associated with improved metabolic health.
[0015] In preferred embodiments, the ketogenic composition is provided as a solid or powder form as opposed to a liquid or gel. Such solid-form ketogenic compositions, in addition to providing the beneficial ketogenic and electrolyte balancing effects described herein, are preferably formulated to provide for ease of handling and manufacturability.
Alternatively, the composition may be in the form of a liquid mouth spray for fast delivery and uptake. In some embodiments, the beneficial ketogenic and electrolytic effects are realized without hampering or overly impacting the manufacturability or ease of handling of the composition.
Alternatively, the composition may be in the form of a liquid mouth spray for fast delivery and uptake. In some embodiments, the beneficial ketogenic and electrolytic effects are realized without hampering or overly impacting the manufacturability or ease of handling of the composition.
[0016] Additional features and advantages will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the embodiments disclosed herein. It is to be understood that both the foregoing brief summary and the following detailed description are exemplary and explanatory only and are not restrictive of the embodiments disclosed herein or as claimed.
DETAILED DESCRIPTION
I. Introduction
DETAILED DESCRIPTION
I. Introduction
[0017] The compound "beta-hydroxybutyrate," also known as 0-hydroxybutyrate, 3-hydroxybutyrate, OFIB, BHB, or beta-hydroxybutyrate, is the deprotonated form of beta-hydroxybutyric acid, which is a hydroxycarboxylic acid having the general formula CH3CH2OHCH2COOH. The deprotonated form present at typical biological pH levels is CH3CH2OHCH2C00-. The general chemical structure shown below represents beta-hydroxybutyrate compounds that may be utilized in the disclosed compositions:
-X
where, X can be hydrogen, metal ion, amino cation such as from an amino acid, alkyl, alkenyl, aryl, or acyl.
-X
where, X can be hydrogen, metal ion, amino cation such as from an amino acid, alkyl, alkenyl, aryl, or acyl.
[0018] When X is a hydrogen, the compound is beta-hydroxybutyric acid. When X
is a metal ion or an amino cation, the compounds is a beta-hydroxybutyrate salt.
When X is alkyl, alkenyl, aryl, or acyl, the compounds is a beta-hydroxybutyrate ester.
The foregoing compounds can be in any desired physical form, such as crystalline, powder, solid, liquid, solution, suspension, or gel.
is a metal ion or an amino cation, the compounds is a beta-hydroxybutyrate salt.
When X is alkyl, alkenyl, aryl, or acyl, the compounds is a beta-hydroxybutyrate ester.
The foregoing compounds can be in any desired physical form, such as crystalline, powder, solid, liquid, solution, suspension, or gel.
[0019] Unless otherwise specified, the term "salt" does not mean or imply any particular physical state, such as a crystalline, powder, other solid form, dissolved in water to form a 5 liquid solution, dispersed in a liquid to form a suspension, or gel. A
salt can be formed in solution, such as by at least partially neutralizing beta-hydroxybutyric acid with a strong or weak base, such as an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate, basic amino acid, and the like.
salt can be formed in solution, such as by at least partially neutralizing beta-hydroxybutyric acid with a strong or weak base, such as an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate, basic amino acid, and the like.
[0020] The beta-hydroxybutyrate mixed salt-acid composition can include a mixture of .. beta-hydroxybutyrate salts and beta-hydroxybutyric acid. Providing beta-hydroxybutyrate in its acid form can be beneficial because of its much quicker absorption response time compared to salt forms. Nonetheless, even though the acid form by itself is a liquid with extremely low pH and unpalatable taste, when made or combined with salt forms and where the amount of beta-hydroxybutyric acid is small relative to the salt forms, the composition can still form a solid, powder or other form typical of salt forms. In such case, the combined salt and acid form of beta-hydroxybutyrate has acceptable pH and taste. BHB
compositions that include both salt and acid forms have advantages, such as increased absorption rate, increased bioavailability, lower electrolyte load, ease of manufacture, significantly improved taste, and reduced need for citric acid or other edible acids to obtain a composition with neutral or acidic pH. It will be appreciated that beneficial effects can also be provided using a mixture of beta-hydroxybutyrate salt(s) and/or ester(s) and the acid form(s) of BHB.
compositions that include both salt and acid forms have advantages, such as increased absorption rate, increased bioavailability, lower electrolyte load, ease of manufacture, significantly improved taste, and reduced need for citric acid or other edible acids to obtain a composition with neutral or acidic pH. It will be appreciated that beneficial effects can also be provided using a mixture of beta-hydroxybutyrate salt(s) and/or ester(s) and the acid form(s) of BHB.
[0021] The term "free beta-hydroxybutyric acid" means the sum of non-deprotonated and deprotonated beta-hydroxybutyric acid molecules. A deprotonated beta-hydroxybutyric acid molecule generally means a molecule that has released a proton to form a hydronium ion (H30+) and a beta-hydroxybutyrate anion (e.g., dissolved in water).
[0022] Free beta-hydroxybutyric acid molecules are typically not deprotonated to any significant degree when contained in a beta-hydroxybutyrate mixed salt-acid composition in dry powder or other solid form. In such cases, the fractional amount of free beta-hydroxybutyric acid in a beta-hydroxybutyrate mixed salt-acid composition on a weight basis is the weight of free beta-hydroxybutyric acid divided by the combined weight of free beta-hydroxybutyric acid and beta-hydroxybutyrate salt(s). On a molar basis, the fractional amount of free beta-hydroxybutyric acid in an beta-hydroxybutyrate mixed salt-acid composition are the molar equivalents of free beta-hydroxybutyric acid divided by the sum of molar equivalents of free beta-hydroxybutyric acid and beta-hydroxybutyrate anions provided by the beta-hydroxybutyrate salt(s).
[0023] When dissolved in water, a portion of the beta-hydroxybutyric acid will typically dissociate into beta-hydroxybutyrate anions and hydronium ions (H30+). As a result, beta-hydroxybutyric acid molecules can exchange protons and cations with dissolved beta-hydroxybutyrate salts. For purposes of defining the relative amounts of beta-hydroxybutyric acid and beta-hydroxybutyrate salt(s) in a beta-hydroxybutyrate mixed salt-acid composition, dissociation of beta-hydroxybutyric acid molecules and the exchange of protons and cations is not understood as changing the molar ratio of free beta-hydroxybutyric acid relative to beta-hydroxybutyrate anions from the beta-hydroxybutyrate salt(s). The total quantity of free beta-hydroxybutyric acid molecules in solution is the sum of dissolved beta-hydroxybutyric acid molecules that are not deprotonated and beta-hydroxybutyrate anions formed by deprotonation of beta-hydroxybutyric acid molecules.
[0024] Stated another way, the total molar equivalents of beta-hydroxybutyric acid in solution, whether or not deprotonated, is understood to be the difference between (i) the sum of molar equivalents of non-deprotonated beta-hydroxybutyric acid molecules and total molar equivalents of beta-hydroxybutyrate anions in solution (from all sources) and (ii) the total molar equivalents of cationic charge provided by cations from the beta-hydroxybutyrate salt compounds (which equals the total molar equivalents of beta-hydroxybutyrate anions provided by the beta-hydroxybutyrate salt(s)). Alkali metal cations such as sodium and potassium provide 1 mole of cationic charge per mole of metal cations.
Alkaline earth metal cations such as magnesium and calcium, on the other hand, provide 2 moles of cationic charge per mole of metal cations. 1 mole of deprotonated beta-hydroxybutyric acid molecules provide 1 mole of anionic charge and one mole of cationic charge.
Alkaline earth metal cations such as magnesium and calcium, on the other hand, provide 2 moles of cationic charge per mole of metal cations. 1 mole of deprotonated beta-hydroxybutyric acid molecules provide 1 mole of anionic charge and one mole of cationic charge.
[0025] In view of the foregoing, the molar fraction of beta-hydroxybutyric acid in solution in relation to total moles of beta-hydroxybutyrate molecules from the beta-hydroxybutyrate mixed salt-acid composition in solution is [(i)-(ii) (i)], and the molar fraction of beta-hydroxybutyrate molecules from the beta-hydroxybutyrate salt(s)) in solution is [(ii) (i)].
Multiplying the molar fraction of each by 100 gives the percentage of each in solution.
Multiplying the molar fraction of each by 100 gives the percentage of each in solution.
[0026] By way of example, if a beta-hydroxybutyrate mixed salt-acid composition in a dry powdered state contained 5% of free non-deprotonated beta-hydroxybutyric acid and 95%
beta-hydroxybutyrate salt(s) on a molar basis, there will be essentially 5 molar equivalents of beta-hydroxybutyric acid molecules and 95 molar equivalents of beta-hydroxybutyrate anions. When there is sufficient water to dissolve all of the beta-hydroxybutyrate salt(s), and if a portion of the beta-hydroxybutyric acid molecules are deprotonated, the molar equivalents of non-deprotonated beta-hydroxybutyric acid will be less than 5%
and the molar equivalents of beta-hydroxybutyrate anions will be greater than 95%. The extent of deprotonation of beta-hydroxybutyric acid in solution is related to solution pH.
beta-hydroxybutyrate salt(s) on a molar basis, there will be essentially 5 molar equivalents of beta-hydroxybutyric acid molecules and 95 molar equivalents of beta-hydroxybutyrate anions. When there is sufficient water to dissolve all of the beta-hydroxybutyrate salt(s), and if a portion of the beta-hydroxybutyric acid molecules are deprotonated, the molar equivalents of non-deprotonated beta-hydroxybutyric acid will be less than 5%
and the molar equivalents of beta-hydroxybutyrate anions will be greater than 95%. The extent of deprotonation of beta-hydroxybutyric acid in solution is related to solution pH.
[0027] Beta-hydroxybutyrate can be utilized by a patient's body as a fuel source during instances of low glucose levels in the subject or when a patient's body is supplemented with a usable form of beta-hydroxybutyrate. Beta-hydroxybutyrate is commonly referred to as a "ketone body".
[0028] As used herein, "ketogenic composition" refers to a mixed beta-hydroxybutyrate salt-acid composition. The composition is formulated to increase ketone body level in a subject, including inducing and/or sustaining a state of elevated ketone bodies at a desired level, such as ketosis, in a subject to which it is administered, while simultaneously promoting or maintaining electrolyte balance in the subject.
[0029] The term "mixed salt" or "multi-salt" is used herein to describe the portion of a ketogenic composition comprising multiple beta-hydroxybutyrate salts. The mixed BHB
salts include a plurality of cation forms (e.g., two, three, four or more) of BHB salt, and the salts are relatively proportioned to promote electrolytic benefits in the subject.
salts include a plurality of cation forms (e.g., two, three, four or more) of BHB salt, and the salts are relatively proportioned to promote electrolytic benefits in the subject.
[0030] As used herein, "subject" or "patient" refers to members of the animal kingdom, including mammals, such as but not limited to, humans and other primates;
rodents, fish, reptiles, and birds. The subject may be any animal requiring therapy, treatment, or prophylaxis, or any animal suspected of requiring therapy, treatment, or prophylaxis.
Prophylaxis means that regiment is undertaken to prevent a possible occurrence, such as where a high glucose or diabetes is identified. "Patient" and "subject" are used interchangeably herein.
rodents, fish, reptiles, and birds. The subject may be any animal requiring therapy, treatment, or prophylaxis, or any animal suspected of requiring therapy, treatment, or prophylaxis.
Prophylaxis means that regiment is undertaken to prevent a possible occurrence, such as where a high glucose or diabetes is identified. "Patient" and "subject" are used interchangeably herein.
[0031] The term "unit dose" refers to a dosage form that is configured to deliver a specified quantity or dose of composition or component thereof Example dosage forms include, but are not limited to, tablets, capsules, powders, food products, food additives, beverages (such as flavored, vitamin fortified, or non-alcoholic), beverage additives (such as flavored, vitamin fortified, or non-alcoholic), candies, suckers, pastilles, food supplements, dietetically acceptable sprays (such as flavored mouth spray), injectables (such as an alcohol-free injectable), and suppositories. Such dosage forms may be configured to provide a full unit dose or fraction thereof (e.g., 1/2, 1/3, or 1/4 of a unit dose).
[0032] Another dosage form that can be used to provide a unit dose of composition or component thereof is a unit dose measuring device, such as a cup, scoop, syringe, dropper, spoon, spatula, or colonic irrigation device, which is configured to hold therein a measured quantity of composition equaling a full unit dose or fraction thereof (e.g., 1/2, 1/3, or 1/4 of a unit dose). For example, a bulk container, such as a carton, box, can, jar, bag, pouch, bottle, jug, or keg, containing several unit doses of composition (e.g., 5-250 or 10-150 unit doses) can be provided to a user together with a unit dose measuring device that is configured to provide a unit dose, or fraction thereof, of composition or component thereof
[0033] A kit for use in providing a composition as disclosed herein in bulk form, while providing unit doses of the composition, may comprise a bulk container holding therein a quantity of composition and a unit dose measuring device configured to provide a unit dose, or fraction thereof, of composition or component thereof One or more unit dose measuring devices may be positioned inside the bulk container at the time of sale, attached to the outside of the bulk container, prepackaged with the bulk container within a larger package, or provided by the seller or manufacture for use with one or multiple bulk containers.
[0034] The kit may include instructions regarding the size of the unit dose, or fraction thereof, and the manner and frequency of administration. The instructions may be provided on the bulk container, prepackaged with the bulk container, placed on packaging material sold with the bulk container, or otherwise provided by the seller or manufacturer (e.g., on websites, mailers, flyers, product literature, etc.) The instructions for use may include a reference on how to use the unit dose measuring device to properly deliver a unit dose or fraction thereof The instructions may additionally or alternatively include a reference to common unit dose measuring devices, such as spoons, spatulas, cups, and the like, not provided with the bulk container (e.g., in case the provided unit dose measuring device is lost or misplaced). In such case, a kit may be constructed by the end user when following instructions provided on or with the bulk container, or otherwise provided by the seller regarding the product and how to properly deliver a unit dose of composition, or fraction thereof
[0035] "Ketosis" as used herein refers to a subject having blood ketone levels within the range of about 0.5 mmol/L and about 16 mmol/L in a subject. Ketosis may improve mitochondrial function, decrease reactive oxygen species production, reduce inflammation and increase the activity of neurotrophic factors. "Keto-adaptation" as used herein refers to prolonged nutritional ketosis (>1 week) to achieve a sustained nonpathological "mild ketosis" or "therapeutic ketosis."
[0036] In some cases, "elevated ketone body level" may not mean that a subject is in a state of "clinical ketosis" but nevertheless has an elevated supply of ketones for producing energy and/or for carrying out other beneficial effects of ketone bodies. For example, a subject that is "ketone adapted" may not necessarily have elevated blood serum levels of ketone bodies but is able to utilize available ketone bodies more rapidly compared to a subject that is not "ketone adapted." In such case, "elevated ketone body level" can refer to the total quantity and/or rate of ketone bodies being utilized by the subject rather than blood plasma levels per se.
[0037] The term "short chain triglycerides" (SCT) refers to molecules having a glycerol backbone attached to three medium chain fatty acids. Short chain fatty acids can range from 2 to 5 carbon atoms in length. Exemplary short chain fatty acids are acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid. An example SCT is tributyrin.
[0038] The term "medium chain triglycerides" (MCT) refers to molecules having a glycerol backbone attached to three medium chain fatty acids. Medium chain fatty acids can range from 6 to 12 carbon atoms in length, and more likely 8 to 10 carbon atoms in length.
Exemplary fatty acids are caprylic acid, also known as octanoic acid, comprising 8 carbon molecules, and capric acid, also known as decanoic acid, comprising 10 carbon molecules.
MCTs, medium chain fatty acids, and mono- and di-glycerides are ketone body precursors that can provide an additional source for the production of ketone bodies independent of beta-hydroxybutyrate.
Exemplary fatty acids are caprylic acid, also known as octanoic acid, comprising 8 carbon molecules, and capric acid, also known as decanoic acid, comprising 10 carbon molecules.
MCTs, medium chain fatty acids, and mono- and di-glycerides are ketone body precursors that can provide an additional source for the production of ketone bodies independent of beta-hydroxybutyrate.
[0039] The term "long chain triglycerides" (LCT) refers to molecules having a glycerol backbone attached to three medium chain fatty acids. Long chain fatty acids can be greater than 12 carbon atoms in length.
[0040] The term "administration" or "administering" is used herein to describe the process in which the mixed salt ketogenic compositions are delivered to a subject. The composition may be administered in various ways including oral, intragastric, and parenteral (referring to intravenous and intra-arterial and other appropriate parenteral routes), among others.
Ketogenic Beta-Hydroxybutyrate Mixed Salt-Acid Compositions
Ketogenic Beta-Hydroxybutyrate Mixed Salt-Acid Compositions
[0041] The administration of beta-hydroxybutyrate mixed salt-acid compositions results in elevated and sustained blood levels of ketone bodies, thereby exploiting the metabolic and physiological advantages of sustained ketosis. Raising the levels of ketone bodies in the blood provides a subject with greater flexibility in diet options as compared to a method that aims to induce and sustain ketosis based on diet alone (e.g., based on fasting and/or limited carbohydrate intake). For example, a subject that has been administered an appropriate amount of beta-hydroxybutyrate mixed salt-acid will be able to eat an occasional carbohydrate or sugar-based food without jeopardizing the ketogenic state and shifting back into a glucose-based metabolic state. Further, such administration facilitates easier transitioning into a ketogenic state while reducing or eliminating the detrimental effects typically associated with entering ketosis.
5 [0042] Subjects entering or maintaining a ketogenic state will often be in a state of electrolyte imbalance due to the metabolic shifts involved with ketosis, including enhanced diuretic effects and changes in insulin profiles. Thus, while there are many benefits to the administration of beta-hydroxybutyrate mixed salt-acid in order to promote or sustain ketosis in a subject, the resulting electrolyte imbalance, and its associated detrimental 10 physiological effects can offset the benefits of ketosis and/or make it more difficult for a subject to maintain ketosis at the desired levels or for a desired length of time.
[0043] Further, because beta-hydroxybutyrate can be administered in salt form, where one or more beta-hydroxybutyrate molecules are the anions to a selected cation, the introduction of additional cation electrolytes can cause or exacerbate electrolyte imbalance in a subject.
For example, a formulation having an overly high level and/or an overly high proportion of a particular form of beta-hydroxybutyrate salt can cause further electrolyte imbalance and/or cause other detrimental health effects. In some circumstances, even if the particular form of beta-hydroxybutyrate salt eases an electrolyte imbalance to some degree, it can introduce other negative and undesirable health effects.
[0044] By way of example, a formulation having an overly high level and/or an overly high proportion of sodium beta-hydroxybutyrate will increase levels of sodium in the subject. While sodium is a necessary nutrient, having levels that are outside of optimal ranges can lead to detrimental effects. High levels of sodium are associated with hypertension and poor cardiovascular health. In particular, high levels of sodium relative to potassium will promote hypertension and raise the risk of cardiovascular disease.
[0045] In another example, a formulation having an overly high level or an overly high proportion of calcium beta-hydroxybutyrate will increase calcium levels in the subject.
While calcium is also a necessary nutrient, and is particularly important for good bone health, excessive calcium may not be fully absorbed into the bones but may instead build up in soft tissues, leading to detrimental calcification and hardening of the tissues and raising the risk of heart disease (e.g., associated with hardened arteries), kidney stones, arthritis, and other problematic conditions. In particular, unduly high levels of calcium relative to magnesium can aggravate these negative effects. Magnesium functions by stimulating the hormone calcitonin and functions to convert vitamin D to its active form so it can promote calcium absorption in the bones as opposed to calcium deposition in soft tissues.
[0046] The administration of beta-hydroxybutyrate salts in inappropriate amounts and proportions can therefore cause or aggravate detrimental health effects.
Further, accounting for imbalances through other dietary options is not always easy or even possible for a subject attempting to maintain a ketogenic state. For example, many of the foods known to have high levels of potassium and/or magnesium, such as whole grains, bananas, avocados, milk, yogurt, oatmeal, corn, peas, potatoes, and squash, contain high levels of carbohydrates and are not compatible with a strict ketogenic diet when consumed in any substantial amount.
[0047] Embodiments disclosed herein provide a therapeutically effective amount of beta-Dr) hydroxybutyrate in the form of a beta-hydroxybutyrate mixed salt-acid.
Beneficially, the beta-hydroxybutyrate mixed salt-acid is formulated to provide a biologically balanced set of cation electrolytes. One or more embodiments therefore provide the advantages of initiating and/or sustaining ketosis while simultaneously promoting positive electrolytic effects.
[0048] In some embodiments, the beta-hydroxybutyrate mixed salt-acid can include one or more salts of alkali metals, alkaline earth metals, transition metals, amino acids, or metabolites of amino acids. Examples include lithium salts, sodium salts, potassium salts, magnesium salts, calcium salts, zinc salts, iron salts (as iron II and/or iron III), chromium salts, manganese salts, cobalt salts, copper salts, molybdenum salts, selenium salts, arginine salts, lysine salts, leucine salts, isoleucine salts, histidine salts, ornithine salts, citrulline salts, glutamine salts, and creatine salts [0049] In some embodiments, the beta-hydroxybutyrate mixed salt-acid includes a plurality of (e.g., at least two, three or four) different cations and is proportioned such that it comprises acceptable quantities and proportions of at least two of lithium beta-hydroxybutyrate, sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, or magnesium beta-hydroxybutyrate.
[0050] In some embodiments, sodium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-50%, or about 8-40%, or about 10-30%, or about 12-25%, or about 14-22%, or about 16-20%, or about 18%, by weight of the BHB mixed salt-acid.
[0051] In some embodiments, potassium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-50%, or about 8-40%, or about 10-30%, or about 12-25%, or about 14-22%, or about 16-20%, or about 18%, by weight of the BHB mixed salt-acid.
[0052] In some embodiments, calcium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-60%, or about 8-50%, or about 10-40%, or about 12-35%, or about 15-30%, or about 18-25%, or about 20-23%, by weight of the BHB mixed salt-acid.
[0053] In some embodiments, magnesium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-60%, or about 8-50%, or about 10-40%, or about 12-35%, or about 15-30%, or about 18-25%, or about 20-23%, by weight of the BHB mixed salt-acid.
[0054] In some embodiments, sodium beta-hydroxybutyrate is included in an amount, by weight, no greater than an amount of potassium beta-hydroxybutyrate in the composition.
This enables administration of necessary sodium and potassium electrolytes, providing a beneficial electrolytic effect to the subject, without causing or aggravating unwanted health effects associated with high sodium to potassium ratios (e.g., hypertension, cardiovascular in .. disease, and other unfavorable effects).
[0055] In some embodiments, calcium beta-hydroxybutyrate is included in an amount, by weight, no greater than an amount of magnesium beta-hydroxybutyrate. This enables administration of necessary calcium and magnesium electrolytes, providing a beneficial electrolytic effect to the subject, without causing or aggravating unwanted health effects associated with high calcium to magnesium ratios (e.g., tissue calcification, poor bone health, and other unfavorable effects).
[0056] In some embodiments, beta-hydroxybutyrate mixed salt-acid compositions can be formulated such that the molar ratio of sodium to potassium ions is no greater than 1, and/or such that the molar ratio of calcium to magnesium ions is no greater than 1.
[0057] The beta-hydroxybutyrate mixed salt-acid compositions disclosed herein comprise a plurality of beta-hydroxybutyrate salts and beta-hydroxybutyric acid. More particularly, the beta-hydroxybutyrate mixed salt-acid composition contains less than 100%
of combined beta-hydroxybutyrate salts and greater than 0% free beta-hydroxybutryic acid, such as up to 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99%, 98.8%, 98.65%, .. 98.5%, 98.35%, 98.2%, 98%, 97.75%, 97.5%, 97.25%, or 97%, and at least 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, or 97%, by molar equivalents of combined beta-hydroxybutyrate salts and at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.35%, 1.5%, 1.65%, 1.8%, 2%, 2.25%, 2.5%, 2.75%, or 3%, and less than 25%, 20%, 15%, 10%, 8%, 6%, 5%, 4%, or 3%, by molar equivalents of free hydroxybutryic acid.
[0058] In some embodiments, a ketogenic composition additionally includes a therapeutically effective amount of vitamin D3. Vitamin D3 works in conjunction with magnesium and calcium to promote good bone health and to prevent undesirable calcification of soft tissues. In preferred embodiments, vitamin D3 is included in an amount such that an average daily dose of the ketogenic composition includes about ("International Units") to about 8000 IU, or about 400 IU to about 4000 IU, or about 600 IU to about 3000 IU of vitamin D3. In some embodiments, vitamin D3 is included in an amount such that an average daily dose of the ketogenic composition includes about 5 lig to about 200 pg, or about 10 pg to about 100 pg, or about 15 pg to about 75 pg of vitamin D3.
[0059] In some embodiments, the ketogenic compositions can include or be administered together with other supplements, such as vitamins, minerals, nootropics, and others known in the art. Examples of vitamins, minerals and herbal supplements that can be added to the ketogenic compositions include one or more of vitamin A, vitamin C, vitamin E, niacin, vitamin B6, folic acid, 5-MTHF, vitamin B12, iodine, zinc, copper, manganese, chromium, Dr) caffeine, theobromine, theacrine, methylliberine, huperzine A, epicatechins, and enzymes [0060] Some embodiments also include one or more additional ketone precursors or supplements. These additional ketone precursors or supplements might include acetoacetate, ketone esters, and/or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream. Other additives include metabolites that enhance the effect or transport of ketone bodies into mitochondria, caffeine, theobromine, and nootropics, such as L-alpha glycerylphosphorylcholine ("alpha GPC").
[0061] Some embodiments include additional beta-hydroxybutyrate salts as part of the mixed salt of the ketogenic composition. For example, some embodiments include one or more transition metal beta-hydroxybutyrate salts. Transition metal cations suitable for use as BHB or other salts include lithium, chromium, manganese, cobalt, copper, zinc, iron, (e.g., as an iron II or iron III cation), molybdenum, and selenium.
[0062] The ketogenic composition can be formulated so that an average daily dose of the composition provides an amount of at least one of the cations of the mixed salt that is within a range of about 0.25 to about 10 times the recommended dietary allowance (RDA) of the of the at least one cation, or about 0.5 to 5 times, or about 0.75 to 2 times the RDA of the at least one cation. For example, the mixed salt-acid composition may be formulated so that when a subject takes a daily amount of the composition, the subject will have consumed amounts cation electrolytes within the foregoing ranges. In some embodiments, the mixed salt-acid composition is formulated so that the at least one cation electrolyte falling within the foregoing ranges after a daily dose of the composition is potassium and/or magnesium.
In some cases, RDA levels may be exceeded without necessarily experiencing toxicity or negative health effects.
[0063] In some embodiments, beta-hydroxybutyrate mixed salt-acid compositions may include one or more beta-hydroxybutyrate salts in which at least some of the cations are provided by one or more amino acids or other organic compounds that have a net positive charge at the pH at which the beta-hydroxybutyrate salts are produced. beta-hydroxybutyrate-amino acid salts can provide soluble forms of beta-hydroxybutyrate without providing electrolytes, such as sodium, potassium, calcium or magnesium. This permits the manufacture of beta-hydroxybutyrate salts with a reduced quantity of electrolytes and/or healthier amount and/or healthier balance of electrolytes, particularly where it is desired to delivered higher quantities of beta-hydroxybutyrate for therapeutic reasons without further increasing electrolyte load. Suitable amino acids for this purpose can include amino acids that contain more than one amine group capable of being protonated to form a compound having a net positive charge, which can provide the counter cation for the beta-hydroxybutyrate anion. Examples include arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or other suitable amino acids or metabolites of amino acids (e.g., creatine). Some amino acids also provide health benefits.
For example, /-arginine can increase nitric oxide in the blood, which dilates blood vessels and improves blood circulation for persons with heart conditions (and may help men suffering from erectile dysfunction).
[0064] In some embodiments, the ketogenic composition may include at least one short chain fatty acid, or a mono-, di- or triglyceride of the at least one short chain fatty acid, where the short chain fatty acid has less than 6 carbons. The composition may include at least one medium chain fatty acid, or a mono-, di- or triglyceride of the at least one medium chain fatty acid, wherein the medium chain fatty acid has from 6 to 12 carbons, preferably from 8 to 10 carbons. Though less preferred, the composition may include at least one long chain fatty acid, or a mono-, di- or triglyceride of the at least one long chain fatty acid, having more than 12 carbons.
[0065] Examples of short chain fatty acids include acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid. Examples of medium chain fatty acids include caproic acid, caprylic acid, capric acid, and lauric acid. Examples of long-chain fatty acids include myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids.
[0066] Examples and sources of the medium chain fatty acid, or an ester thereof such as a medium chain triglyceride, include coconut oil, coconut milk powder, fractionated coconut oil, palm oil, palm kernel oil, caprylic acid, capric acid, isolated medium chain fatty acids, such as isolated hexanoic acid, isolated octanoic acid, isolated decanoic acid, medium chain triglycerides either purified or in natural form such as coconut oil, and ester derivatives of the medium chain fatty acids ethoxylated triglyceride, enone triglyceride derivatives, aldehyde triglyceride derivatives, monoglyceride derivatives, diglyceride derivatives, and triglyceride derivatives, and salts of the medium chain triglycerides. Ester derivatives 5 optionally include alkyl ester derivatives, such as methyl, ethyl, propyl, butyl, hexyl, etc.
[0067] In some embodiments, the ketogenic composition may be provided as a solid or powder form as opposed to a liquid or gel form. Such solid-form ketogenic compositions, in addition to promoting beneficial ketogenic effects and electrolytic effects described herein, are formulated so as to provide for sufficient ease of handling and manufacturability.
10 .. For example, in a mixed salt-acid formulation of various beta-hydroxybutyrate salts, certain salts will exhibit different material properties (e.g., hygroscopicity), and the relative amounts of the different salts in the mixed salt formulation may affect the overall properties of the composition.
[0068] In an alternative embodiment, the ketogenic composition may be provided as a 15 liquid, such as in the form of a shot or mouth spray for fast delivery and absorption. Liquid forms may include one or more liquid carriers, such as water, ethanol, glycerin, propylene glycol, 1, 3-propandiol, and the like, into which the BHB mixed salt-acid compositions are dissolved or dispersed. The composition may include flavoring agents that help mask the taste of beta-hydroxybutyrate compounds. These include essential oils, such as peppermint, natural and artificial sweeteners, and other flavorants known in the art.
[0069] Manufacturing of the mixed salt-acid formulations described herein has demonstrated that certain beta-hydroxybutyrate salts, in particular potassium beta-hydroxybutyrate and magnesium beta-hydroxybutyrate, exhibit greater hygroscopicity than other beta-hydroxybutyrate salts. Improperly proportioning beta-hydroxybutyrate salts can create formulations that do not flow or handle well, increasing manufacturing costs and potentially decreasing the shelf-life, stability and efficacy of the ketogenic composition product.
[0070] Accordingly, compositions described herein can be formulated and balanced so as to provide the ketogenic and electrolyte benefits and advantages described above, while not unduly or unacceptably disrupting manufacturability of the composition. At least some embodiments include different beta-hydroxybutyrate salts in proportions that provide sufficient calcium BHB and/or sodium BHB (which typically promote manufacturability and handling) without overly including these salts at overly high levels which promote harmful health effects. Likewise, at least some embodiments include potassium BHB and/or magnesium BHB (which typically hampers manufacturability and handling) in amounts sufficient to balance the calcium and/or sodium BHB but not in excessive amounts.
[0071] In some embodiments, the beta-hydroxybutyrate mixed salt-acid composition includes a dietetically or pharmaceutically acceptable carrier. Examples include powders, liquids, tablets, capsules, food products, food additives, beverages, vitamin fortified beverages, beverage additives, candies, suckers, pastilles, food supplements, sprays, injectables, and suppositories [0072] In some embodiments, ketogenic compositions may further include one or more additional components configured to lower the hygroscopicity of the composition. For example, various anticaking agents, flow agents, and/or moisture absorbers, in types and amounts that are safe for consumption, may be included. Such additional components may include one or more of an aluminosilicate, ferrocyanide, carbonate or bicarbonate salt, silicate (e.g., sodium or calcium silicate), silica, phosphate salt (e.g., di-or tricalcium phosphate), talc, powdered cellulose, calcium carbonate, and the like.
III. Administration [0073] Ketogenic compositions described herein may be administered to a subject in therapeutically effective dosages and/or in frequencies to induce or sustain ketosis. In some embodiments, a single dose will include an amount of beta-hydroxybutyrate mixed salt-acid ranging from about 1-50 grams, or about 2-40 grams, or about 5-30 grams, or about 10-20 grams. In some embodiments, the ketogenic compositions can include or be administered together with supplements or other additives described herein.
[0074] In some embodiments, the subject preferably follows a ketogenic diet that restricts intake of carbohydrates and protein during the period of administration of the composition.
In one example embodiment, the subject may restrict the dietary intake to a ratio of about 65% fat, about 25% protein, and about 10% carbohydrates. The resulting therapeutic ketosis provides a rapid and sustained keto-adaptation as a metabolic therapy for a wide range of metabolic disorders, and provides nutritional support for therapeutic fasting, weight loss, and performance enhancement. As such, the composition is typically administered once per day, twice per day, or three times per day to a subject desiring to promote and/or sustain a state of ketosis.
[0075] In some embodiments, a ketogenic composition is administered orally, as in solid and/or powdered form, such as in a powdered mixture (e.g., powder filled gelatin capsules), hard-pressed tablets, dissolved in water or juice, or other oral administration route known to those skilled in the art.
[0076] In some embodiments, multiple doses of the composition can be administered. The frequency of administration of the composition can vary depending on any of a variety of factors, such as timing of treatment from previous treatments, objectives of the treatment, and the like. The duration of administration of the composition (e.g., the period of time over which the agent is administered), can vary depending on any of a variety of factors, including subject response, desired effect of treatment, etc.
[0077] The amount of the composition to be administered can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the like. The "therapeutically effective to amount"
is that amount necessary to promote a therapeutically effective result in vivo (i.e., therapeutic ketosis). In accordance with the present disclosure, a suitable single dose size is a dose that is capable of preventing or alleviating (reducing or eliminating) a symptom in a patient when administered one or more times over a suitable time period.
[0078] The amount of composition administered will depend on potency, absorption, distribution, metabolism, and excretion rates of beta-hydroxybutyrate and/or corresponding electrolytes, the method of administration, and the particular disorder being treated, as well as other factors known to those of skill in the art. The dose should be sufficient to effect a desirable response, such as a therapeutic or prophylactic response against a particular disorder or condition, taking into account the severity of the condition to be alleviated. The composition may be administered once, or it may be divided and administered over intervals of time. It is to be understood that administration may be adjusted according to individual need and professional judgment of a person administrating or supervising the administration of the composition.
IV. Examples [0079] The following is a description of exemplary beta-hydroxybutyrate mixed salt-acid compositions useful for inducing and/or sustaining a ketogenic state in a subject to which they are administered while simultaneously providing a balanced set of cationic electrolytes.
Example 1 [0080] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 23%
by weight, potassium BHB at 23% by weight, calcium BHB at 27% by weight, and magnesium BHB at 27% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 2 [0081] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 18%
by weight, potassium BHB at 18% by weight, calcium BHB at 32% by weight, and magnesium BHB at 32% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a 1() ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 3 [0082] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 20% by weight, calcium BHB at 30% by weight, and magnesium BHB at 35% by weight. Vitamin D3 is added in an amount of 800 IU for every grams of the BHB mixed salt-acid (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid 20 is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 4 [0083] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 35% by weight, and magnesium BHB at 35% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 5 [0084] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 30%
by weight, potassium BHB at 30% by weight, calcium BHB at 20% by weight, and magnesium BHB at 20% by weight. Vitamin D3 is added in an amount of 1200 IU
for every 15 grams of the BHB mixed salt-acid (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 6 in [0085] A
beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 18% by weight, magnesium BHB at 18% by weight, zinc BHB at 17% by weight, and iron BHB at 17% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid.
The BHB
mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 7 [0086] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 20%
by weight, potassium BHB at 20% by weight, calcium BHB at 20% by weight, magnesium BHB at 20% by weight, and zinc BHB at 20% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 8 [0087] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 25% by weight, calcium BHB at 20% by weight, magnesium BHB at 25% by weight, and iron BHB at 15% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
5 Example 9 [0088] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 20% by weight, magnesium BHB at 20% by weight, zinc BHB at 20% by weight, and iron BHB at 10% by weight.
Vitamin D3 is added in an amount of 600 IU for every 10 grams of the BHB mixed salt 1() (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or 15 drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray or shot.
Example 10 [0089] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 23%
by weight, potassium BHB at 23% by weight, calcium BHB at 27% by weight, and 20 magnesium BHB at 27% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 11 [0090] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 25%
by weight, potassium BHB at 25% by weight, calcium BHB at 25% by weight, and magnesium BHB at 25% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is mixed with an anti-caking agent, which is safe for human consumption, at a ratio of 4 to 1 to form a ketogenic composition readily administered to a subject, such as in powder form as a dietary supplement mixed with food or drink, or in the form of one or more capsules or tablets.
Example 12 [0091] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions includes at least one medium chain fatty acid source selected from a medium chain fatty acid having .. 6 to 12 carbons, preferably 8 to 10 carbons, monoglyceride of the medium chain fatty acid, diglyceride of the medium chain fatty acid, or triglyceride of the medium chain fatty acid to provide a ketogenic composition that provides prolonged ketosis over a greater period of time than would be provided by a given dosage of BHB mixed salt-acid by itself The ratio of medium chain fatty acid source to BHB mixed salt-acid composition is 4:1, 3:1, 2:1, 1:1 to or 1:2.
Example 13 [0092] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions includes one or more BHB salts of a cationic amino acid selected from arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or metabolite of an amino acid, such as creatine). The BHB-amino acid salt decreases the ratio of electrolytes to BHB
anions in the composition.
Example 14 [0093] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions is combined with at least one short chain fatty acid source selected from a short chain fatty acid having less than 6 carbons, monoglyceride of the short chain fatty acid, diglyceride of the short chain fatty acid, or triglyceride of the short chain fatty acid.
Example 15 [0094] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions is combined with at least one long chain fatty acid source selected from a long chain fatty acid having more than 12 carbons, monoglyceride of the long chain fatty acid, diglyceride of the long chain fatty acid, or triglyceride of the long chain fatty acid.
[0095] The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
5 [0042] Subjects entering or maintaining a ketogenic state will often be in a state of electrolyte imbalance due to the metabolic shifts involved with ketosis, including enhanced diuretic effects and changes in insulin profiles. Thus, while there are many benefits to the administration of beta-hydroxybutyrate mixed salt-acid in order to promote or sustain ketosis in a subject, the resulting electrolyte imbalance, and its associated detrimental 10 physiological effects can offset the benefits of ketosis and/or make it more difficult for a subject to maintain ketosis at the desired levels or for a desired length of time.
[0043] Further, because beta-hydroxybutyrate can be administered in salt form, where one or more beta-hydroxybutyrate molecules are the anions to a selected cation, the introduction of additional cation electrolytes can cause or exacerbate electrolyte imbalance in a subject.
For example, a formulation having an overly high level and/or an overly high proportion of a particular form of beta-hydroxybutyrate salt can cause further electrolyte imbalance and/or cause other detrimental health effects. In some circumstances, even if the particular form of beta-hydroxybutyrate salt eases an electrolyte imbalance to some degree, it can introduce other negative and undesirable health effects.
[0044] By way of example, a formulation having an overly high level and/or an overly high proportion of sodium beta-hydroxybutyrate will increase levels of sodium in the subject. While sodium is a necessary nutrient, having levels that are outside of optimal ranges can lead to detrimental effects. High levels of sodium are associated with hypertension and poor cardiovascular health. In particular, high levels of sodium relative to potassium will promote hypertension and raise the risk of cardiovascular disease.
[0045] In another example, a formulation having an overly high level or an overly high proportion of calcium beta-hydroxybutyrate will increase calcium levels in the subject.
While calcium is also a necessary nutrient, and is particularly important for good bone health, excessive calcium may not be fully absorbed into the bones but may instead build up in soft tissues, leading to detrimental calcification and hardening of the tissues and raising the risk of heart disease (e.g., associated with hardened arteries), kidney stones, arthritis, and other problematic conditions. In particular, unduly high levels of calcium relative to magnesium can aggravate these negative effects. Magnesium functions by stimulating the hormone calcitonin and functions to convert vitamin D to its active form so it can promote calcium absorption in the bones as opposed to calcium deposition in soft tissues.
[0046] The administration of beta-hydroxybutyrate salts in inappropriate amounts and proportions can therefore cause or aggravate detrimental health effects.
Further, accounting for imbalances through other dietary options is not always easy or even possible for a subject attempting to maintain a ketogenic state. For example, many of the foods known to have high levels of potassium and/or magnesium, such as whole grains, bananas, avocados, milk, yogurt, oatmeal, corn, peas, potatoes, and squash, contain high levels of carbohydrates and are not compatible with a strict ketogenic diet when consumed in any substantial amount.
[0047] Embodiments disclosed herein provide a therapeutically effective amount of beta-Dr) hydroxybutyrate in the form of a beta-hydroxybutyrate mixed salt-acid.
Beneficially, the beta-hydroxybutyrate mixed salt-acid is formulated to provide a biologically balanced set of cation electrolytes. One or more embodiments therefore provide the advantages of initiating and/or sustaining ketosis while simultaneously promoting positive electrolytic effects.
[0048] In some embodiments, the beta-hydroxybutyrate mixed salt-acid can include one or more salts of alkali metals, alkaline earth metals, transition metals, amino acids, or metabolites of amino acids. Examples include lithium salts, sodium salts, potassium salts, magnesium salts, calcium salts, zinc salts, iron salts (as iron II and/or iron III), chromium salts, manganese salts, cobalt salts, copper salts, molybdenum salts, selenium salts, arginine salts, lysine salts, leucine salts, isoleucine salts, histidine salts, ornithine salts, citrulline salts, glutamine salts, and creatine salts [0049] In some embodiments, the beta-hydroxybutyrate mixed salt-acid includes a plurality of (e.g., at least two, three or four) different cations and is proportioned such that it comprises acceptable quantities and proportions of at least two of lithium beta-hydroxybutyrate, sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, or magnesium beta-hydroxybutyrate.
[0050] In some embodiments, sodium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-50%, or about 8-40%, or about 10-30%, or about 12-25%, or about 14-22%, or about 16-20%, or about 18%, by weight of the BHB mixed salt-acid.
[0051] In some embodiments, potassium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-50%, or about 8-40%, or about 10-30%, or about 12-25%, or about 14-22%, or about 16-20%, or about 18%, by weight of the BHB mixed salt-acid.
[0052] In some embodiments, calcium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-60%, or about 8-50%, or about 10-40%, or about 12-35%, or about 15-30%, or about 18-25%, or about 20-23%, by weight of the BHB mixed salt-acid.
[0053] In some embodiments, magnesium beta-hydroxybutyrate is included in a range of about 5-70%, or about 6-60%, or about 8-50%, or about 10-40%, or about 12-35%, or about 15-30%, or about 18-25%, or about 20-23%, by weight of the BHB mixed salt-acid.
[0054] In some embodiments, sodium beta-hydroxybutyrate is included in an amount, by weight, no greater than an amount of potassium beta-hydroxybutyrate in the composition.
This enables administration of necessary sodium and potassium electrolytes, providing a beneficial electrolytic effect to the subject, without causing or aggravating unwanted health effects associated with high sodium to potassium ratios (e.g., hypertension, cardiovascular in .. disease, and other unfavorable effects).
[0055] In some embodiments, calcium beta-hydroxybutyrate is included in an amount, by weight, no greater than an amount of magnesium beta-hydroxybutyrate. This enables administration of necessary calcium and magnesium electrolytes, providing a beneficial electrolytic effect to the subject, without causing or aggravating unwanted health effects associated with high calcium to magnesium ratios (e.g., tissue calcification, poor bone health, and other unfavorable effects).
[0056] In some embodiments, beta-hydroxybutyrate mixed salt-acid compositions can be formulated such that the molar ratio of sodium to potassium ions is no greater than 1, and/or such that the molar ratio of calcium to magnesium ions is no greater than 1.
[0057] The beta-hydroxybutyrate mixed salt-acid compositions disclosed herein comprise a plurality of beta-hydroxybutyrate salts and beta-hydroxybutyric acid. More particularly, the beta-hydroxybutyrate mixed salt-acid composition contains less than 100%
of combined beta-hydroxybutyrate salts and greater than 0% free beta-hydroxybutryic acid, such as up to 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99%, 98.8%, 98.65%, .. 98.5%, 98.35%, 98.2%, 98%, 97.75%, 97.5%, 97.25%, or 97%, and at least 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, or 97%, by molar equivalents of combined beta-hydroxybutyrate salts and at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.35%, 1.5%, 1.65%, 1.8%, 2%, 2.25%, 2.5%, 2.75%, or 3%, and less than 25%, 20%, 15%, 10%, 8%, 6%, 5%, 4%, or 3%, by molar equivalents of free hydroxybutryic acid.
[0058] In some embodiments, a ketogenic composition additionally includes a therapeutically effective amount of vitamin D3. Vitamin D3 works in conjunction with magnesium and calcium to promote good bone health and to prevent undesirable calcification of soft tissues. In preferred embodiments, vitamin D3 is included in an amount such that an average daily dose of the ketogenic composition includes about ("International Units") to about 8000 IU, or about 400 IU to about 4000 IU, or about 600 IU to about 3000 IU of vitamin D3. In some embodiments, vitamin D3 is included in an amount such that an average daily dose of the ketogenic composition includes about 5 lig to about 200 pg, or about 10 pg to about 100 pg, or about 15 pg to about 75 pg of vitamin D3.
[0059] In some embodiments, the ketogenic compositions can include or be administered together with other supplements, such as vitamins, minerals, nootropics, and others known in the art. Examples of vitamins, minerals and herbal supplements that can be added to the ketogenic compositions include one or more of vitamin A, vitamin C, vitamin E, niacin, vitamin B6, folic acid, 5-MTHF, vitamin B12, iodine, zinc, copper, manganese, chromium, Dr) caffeine, theobromine, theacrine, methylliberine, huperzine A, epicatechins, and enzymes [0060] Some embodiments also include one or more additional ketone precursors or supplements. These additional ketone precursors or supplements might include acetoacetate, ketone esters, and/or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream. Other additives include metabolites that enhance the effect or transport of ketone bodies into mitochondria, caffeine, theobromine, and nootropics, such as L-alpha glycerylphosphorylcholine ("alpha GPC").
[0061] Some embodiments include additional beta-hydroxybutyrate salts as part of the mixed salt of the ketogenic composition. For example, some embodiments include one or more transition metal beta-hydroxybutyrate salts. Transition metal cations suitable for use as BHB or other salts include lithium, chromium, manganese, cobalt, copper, zinc, iron, (e.g., as an iron II or iron III cation), molybdenum, and selenium.
[0062] The ketogenic composition can be formulated so that an average daily dose of the composition provides an amount of at least one of the cations of the mixed salt that is within a range of about 0.25 to about 10 times the recommended dietary allowance (RDA) of the of the at least one cation, or about 0.5 to 5 times, or about 0.75 to 2 times the RDA of the at least one cation. For example, the mixed salt-acid composition may be formulated so that when a subject takes a daily amount of the composition, the subject will have consumed amounts cation electrolytes within the foregoing ranges. In some embodiments, the mixed salt-acid composition is formulated so that the at least one cation electrolyte falling within the foregoing ranges after a daily dose of the composition is potassium and/or magnesium.
In some cases, RDA levels may be exceeded without necessarily experiencing toxicity or negative health effects.
[0063] In some embodiments, beta-hydroxybutyrate mixed salt-acid compositions may include one or more beta-hydroxybutyrate salts in which at least some of the cations are provided by one or more amino acids or other organic compounds that have a net positive charge at the pH at which the beta-hydroxybutyrate salts are produced. beta-hydroxybutyrate-amino acid salts can provide soluble forms of beta-hydroxybutyrate without providing electrolytes, such as sodium, potassium, calcium or magnesium. This permits the manufacture of beta-hydroxybutyrate salts with a reduced quantity of electrolytes and/or healthier amount and/or healthier balance of electrolytes, particularly where it is desired to delivered higher quantities of beta-hydroxybutyrate for therapeutic reasons without further increasing electrolyte load. Suitable amino acids for this purpose can include amino acids that contain more than one amine group capable of being protonated to form a compound having a net positive charge, which can provide the counter cation for the beta-hydroxybutyrate anion. Examples include arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or other suitable amino acids or metabolites of amino acids (e.g., creatine). Some amino acids also provide health benefits.
For example, /-arginine can increase nitric oxide in the blood, which dilates blood vessels and improves blood circulation for persons with heart conditions (and may help men suffering from erectile dysfunction).
[0064] In some embodiments, the ketogenic composition may include at least one short chain fatty acid, or a mono-, di- or triglyceride of the at least one short chain fatty acid, where the short chain fatty acid has less than 6 carbons. The composition may include at least one medium chain fatty acid, or a mono-, di- or triglyceride of the at least one medium chain fatty acid, wherein the medium chain fatty acid has from 6 to 12 carbons, preferably from 8 to 10 carbons. Though less preferred, the composition may include at least one long chain fatty acid, or a mono-, di- or triglyceride of the at least one long chain fatty acid, having more than 12 carbons.
[0065] Examples of short chain fatty acids include acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid. Examples of medium chain fatty acids include caproic acid, caprylic acid, capric acid, and lauric acid. Examples of long-chain fatty acids include myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids.
[0066] Examples and sources of the medium chain fatty acid, or an ester thereof such as a medium chain triglyceride, include coconut oil, coconut milk powder, fractionated coconut oil, palm oil, palm kernel oil, caprylic acid, capric acid, isolated medium chain fatty acids, such as isolated hexanoic acid, isolated octanoic acid, isolated decanoic acid, medium chain triglycerides either purified or in natural form such as coconut oil, and ester derivatives of the medium chain fatty acids ethoxylated triglyceride, enone triglyceride derivatives, aldehyde triglyceride derivatives, monoglyceride derivatives, diglyceride derivatives, and triglyceride derivatives, and salts of the medium chain triglycerides. Ester derivatives 5 optionally include alkyl ester derivatives, such as methyl, ethyl, propyl, butyl, hexyl, etc.
[0067] In some embodiments, the ketogenic composition may be provided as a solid or powder form as opposed to a liquid or gel form. Such solid-form ketogenic compositions, in addition to promoting beneficial ketogenic effects and electrolytic effects described herein, are formulated so as to provide for sufficient ease of handling and manufacturability.
10 .. For example, in a mixed salt-acid formulation of various beta-hydroxybutyrate salts, certain salts will exhibit different material properties (e.g., hygroscopicity), and the relative amounts of the different salts in the mixed salt formulation may affect the overall properties of the composition.
[0068] In an alternative embodiment, the ketogenic composition may be provided as a 15 liquid, such as in the form of a shot or mouth spray for fast delivery and absorption. Liquid forms may include one or more liquid carriers, such as water, ethanol, glycerin, propylene glycol, 1, 3-propandiol, and the like, into which the BHB mixed salt-acid compositions are dissolved or dispersed. The composition may include flavoring agents that help mask the taste of beta-hydroxybutyrate compounds. These include essential oils, such as peppermint, natural and artificial sweeteners, and other flavorants known in the art.
[0069] Manufacturing of the mixed salt-acid formulations described herein has demonstrated that certain beta-hydroxybutyrate salts, in particular potassium beta-hydroxybutyrate and magnesium beta-hydroxybutyrate, exhibit greater hygroscopicity than other beta-hydroxybutyrate salts. Improperly proportioning beta-hydroxybutyrate salts can create formulations that do not flow or handle well, increasing manufacturing costs and potentially decreasing the shelf-life, stability and efficacy of the ketogenic composition product.
[0070] Accordingly, compositions described herein can be formulated and balanced so as to provide the ketogenic and electrolyte benefits and advantages described above, while not unduly or unacceptably disrupting manufacturability of the composition. At least some embodiments include different beta-hydroxybutyrate salts in proportions that provide sufficient calcium BHB and/or sodium BHB (which typically promote manufacturability and handling) without overly including these salts at overly high levels which promote harmful health effects. Likewise, at least some embodiments include potassium BHB and/or magnesium BHB (which typically hampers manufacturability and handling) in amounts sufficient to balance the calcium and/or sodium BHB but not in excessive amounts.
[0071] In some embodiments, the beta-hydroxybutyrate mixed salt-acid composition includes a dietetically or pharmaceutically acceptable carrier. Examples include powders, liquids, tablets, capsules, food products, food additives, beverages, vitamin fortified beverages, beverage additives, candies, suckers, pastilles, food supplements, sprays, injectables, and suppositories [0072] In some embodiments, ketogenic compositions may further include one or more additional components configured to lower the hygroscopicity of the composition. For example, various anticaking agents, flow agents, and/or moisture absorbers, in types and amounts that are safe for consumption, may be included. Such additional components may include one or more of an aluminosilicate, ferrocyanide, carbonate or bicarbonate salt, silicate (e.g., sodium or calcium silicate), silica, phosphate salt (e.g., di-or tricalcium phosphate), talc, powdered cellulose, calcium carbonate, and the like.
III. Administration [0073] Ketogenic compositions described herein may be administered to a subject in therapeutically effective dosages and/or in frequencies to induce or sustain ketosis. In some embodiments, a single dose will include an amount of beta-hydroxybutyrate mixed salt-acid ranging from about 1-50 grams, or about 2-40 grams, or about 5-30 grams, or about 10-20 grams. In some embodiments, the ketogenic compositions can include or be administered together with supplements or other additives described herein.
[0074] In some embodiments, the subject preferably follows a ketogenic diet that restricts intake of carbohydrates and protein during the period of administration of the composition.
In one example embodiment, the subject may restrict the dietary intake to a ratio of about 65% fat, about 25% protein, and about 10% carbohydrates. The resulting therapeutic ketosis provides a rapid and sustained keto-adaptation as a metabolic therapy for a wide range of metabolic disorders, and provides nutritional support for therapeutic fasting, weight loss, and performance enhancement. As such, the composition is typically administered once per day, twice per day, or three times per day to a subject desiring to promote and/or sustain a state of ketosis.
[0075] In some embodiments, a ketogenic composition is administered orally, as in solid and/or powdered form, such as in a powdered mixture (e.g., powder filled gelatin capsules), hard-pressed tablets, dissolved in water or juice, or other oral administration route known to those skilled in the art.
[0076] In some embodiments, multiple doses of the composition can be administered. The frequency of administration of the composition can vary depending on any of a variety of factors, such as timing of treatment from previous treatments, objectives of the treatment, and the like. The duration of administration of the composition (e.g., the period of time over which the agent is administered), can vary depending on any of a variety of factors, including subject response, desired effect of treatment, etc.
[0077] The amount of the composition to be administered can vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, and the like. The "therapeutically effective to amount"
is that amount necessary to promote a therapeutically effective result in vivo (i.e., therapeutic ketosis). In accordance with the present disclosure, a suitable single dose size is a dose that is capable of preventing or alleviating (reducing or eliminating) a symptom in a patient when administered one or more times over a suitable time period.
[0078] The amount of composition administered will depend on potency, absorption, distribution, metabolism, and excretion rates of beta-hydroxybutyrate and/or corresponding electrolytes, the method of administration, and the particular disorder being treated, as well as other factors known to those of skill in the art. The dose should be sufficient to effect a desirable response, such as a therapeutic or prophylactic response against a particular disorder or condition, taking into account the severity of the condition to be alleviated. The composition may be administered once, or it may be divided and administered over intervals of time. It is to be understood that administration may be adjusted according to individual need and professional judgment of a person administrating or supervising the administration of the composition.
IV. Examples [0079] The following is a description of exemplary beta-hydroxybutyrate mixed salt-acid compositions useful for inducing and/or sustaining a ketogenic state in a subject to which they are administered while simultaneously providing a balanced set of cationic electrolytes.
Example 1 [0080] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 23%
by weight, potassium BHB at 23% by weight, calcium BHB at 27% by weight, and magnesium BHB at 27% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 2 [0081] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 18%
by weight, potassium BHB at 18% by weight, calcium BHB at 32% by weight, and magnesium BHB at 32% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a 1() ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 3 [0082] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 20% by weight, calcium BHB at 30% by weight, and magnesium BHB at 35% by weight. Vitamin D3 is added in an amount of 800 IU for every grams of the BHB mixed salt-acid (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid 20 is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 4 [0083] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 35% by weight, and magnesium BHB at 35% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 5 [0084] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 30%
by weight, potassium BHB at 30% by weight, calcium BHB at 20% by weight, and magnesium BHB at 20% by weight. Vitamin D3 is added in an amount of 1200 IU
for every 15 grams of the BHB mixed salt-acid (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 6 in [0085] A
beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 18% by weight, magnesium BHB at 18% by weight, zinc BHB at 17% by weight, and iron BHB at 17% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB
mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid.
The BHB
mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 7 [0086] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 20%
by weight, potassium BHB at 20% by weight, calcium BHB at 20% by weight, magnesium BHB at 20% by weight, and zinc BHB at 20% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 8 [0087] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 25% by weight, calcium BHB at 20% by weight, magnesium BHB at 25% by weight, and iron BHB at 15% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
5 Example 9 [0088] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 15%
by weight, potassium BHB at 15% by weight, calcium BHB at 20% by weight, magnesium BHB at 20% by weight, zinc BHB at 20% by weight, and iron BHB at 10% by weight.
Vitamin D3 is added in an amount of 600 IU for every 10 grams of the BHB mixed salt 1() (representing an average daily dose). At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or 15 drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray or shot.
Example 10 [0089] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 23%
by weight, potassium BHB at 23% by weight, calcium BHB at 27% by weight, and 20 magnesium BHB at 27% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is readily administered as a ketogenic composition, such as in powder form as a dietary supplement mixed with food or drink, in the form of one or more capsules or tablets, or in liquid form such as a mouth spray.
Example 11 [0090] A beta-hydroxybutyrate mixed salt-acid is prepared by mixing sodium BHB
at 25%
by weight, potassium BHB at 25% by weight, calcium BHB at 25% by weight, and magnesium BHB at 25% by weight. At least one of the beta-hydroxybutyrate salts includes an amount of free beta-hydroxybutyric acid and/or an additional amount of free beta-hydroxybutyric acid is added to the BHB mixed salts to provide about 1-3% by weigh of free beta-hydroxybutyric acid. The BHB mixed salt-acid is mixed with an anti-caking agent, which is safe for human consumption, at a ratio of 4 to 1 to form a ketogenic composition readily administered to a subject, such as in powder form as a dietary supplement mixed with food or drink, or in the form of one or more capsules or tablets.
Example 12 [0091] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions includes at least one medium chain fatty acid source selected from a medium chain fatty acid having .. 6 to 12 carbons, preferably 8 to 10 carbons, monoglyceride of the medium chain fatty acid, diglyceride of the medium chain fatty acid, or triglyceride of the medium chain fatty acid to provide a ketogenic composition that provides prolonged ketosis over a greater period of time than would be provided by a given dosage of BHB mixed salt-acid by itself The ratio of medium chain fatty acid source to BHB mixed salt-acid composition is 4:1, 3:1, 2:1, 1:1 to or 1:2.
Example 13 [0092] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions includes one or more BHB salts of a cationic amino acid selected from arginine, lysine, leucine, iso-leucine, histidine, ornithine, citrulline, L-glutamine, or metabolite of an amino acid, such as creatine). The BHB-amino acid salt decreases the ratio of electrolytes to BHB
anions in the composition.
Example 14 [0093] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions is combined with at least one short chain fatty acid source selected from a short chain fatty acid having less than 6 carbons, monoglyceride of the short chain fatty acid, diglyceride of the short chain fatty acid, or triglyceride of the short chain fatty acid.
Example 15 [0094] Any of the foregoing beta-hydroxybutyrate mixed salt-acid compositions is combined with at least one long chain fatty acid source selected from a long chain fatty acid having more than 12 carbons, monoglyceride of the long chain fatty acid, diglyceride of the long chain fatty acid, or triglyceride of the long chain fatty acid.
[0095] The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
Claims (20)
1. A beta-hydroxybutyrate mixed acid-salt composition for increasing ketone level in a subject, comprising:
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate;
wherein the composition is in solid and/or powder form.
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate;
wherein the composition is in solid and/or powder form.
2. The composition of claim 1, wherein the composition comprises at least three of:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate.
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate.
3. The composition of claim 1 or 2, wherein the composition comprises:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; and magnesium beta-hydroxybutyrate.
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; and magnesium beta-hydroxybutyrate.
4. The composition of any one of claims 1-3, wherein the sodium beta-hydroxybutyrate, the potassium beta-hydroxybutyrate, the calcium beta-hydroxybutyrate, and the magnesium beta-hydroxybutyrate are included in relative proportions so that a quantity of the composition that provides the recommended daily allowance (RDA) of calcium provides no more than the RDA for each of sodium, potassium, and magnesium.
5. The composition of any one of claims 1-4, wherein the composition comprises 5-70% by weight of sodium beta-hydroxybutyrate.
6. The composition of any one of claims 1-5, wherein the composition comprises 5-70% by weight of potassium beta-hydroxybutyrate.
7. The composition of any one of claims 1-6, wherein the composition comprises 5-70% by weight of magnesium beta-hydroxybutyrate.
8. The composition of any one of claims 1-7, wherein the composition comprises 5-70% by weight of calcium beta-hydroxybutyrate.
9. The composition of any one of claims 1-8, wherein the composition comprises 90%
to 99.9% by molar equivalents of combined beta-hydroxybutyrate salts and 10%
to 0.1% by molar equivalents of beta-hydroxybutyric acid.
to 99.9% by molar equivalents of combined beta-hydroxybutyrate salts and 10%
to 0.1% by molar equivalents of beta-hydroxybutyric acid.
10. The composition of any one of claims 1-9, wherein the composition comprises 94%
to 99.5% by molar equivalents of combined beta-hydroxybutyrate salts and 6% to 0.5% by molar equivalents of beta-hydroxybutyric acid.
to 99.5% by molar equivalents of combined beta-hydroxybutyrate salts and 6% to 0.5% by molar equivalents of beta-hydroxybutyric acid.
11. The composition of any one of claims 1-10, wherein the composition comprises 96%
to 99% by molar equivalents of combined beta-hydroxybutyrate salts and 4% to 1% by molar equivalents of beta-hydroxybutyric acid.
to 99% by molar equivalents of combined beta-hydroxybutyrate salts and 4% to 1% by molar equivalents of beta-hydroxybutyric acid.
12. The composition of any one of claims 1-11, further comprising at least one short chain fatty acid having less than 6 carbons, or a mono-, di- or triglyceride of the at least one short chain fatty acid.
13. The composition of any one of claims 1-12, further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.
14. A beta-hydroxybutyrate mixed acid-salt composition for increasing ketone level in a subject, comprising:
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
Sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate;
wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository.
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
Sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate;
wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository.
15. The composition of claim 14, wherein the composition comprises 94% to 99.5% by molar equivalents of combined beta-hydroxybutyrate salts and 6% to 0.5% by molar equivalents of beta-hydroxybutyric acid.
16. The composition of claim 14 or 15, further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.
17. A beta-hydroxybutyrate mixed acid-salt composition for increasing ketone level in a subject, comprising:
a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository;
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate.
a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository;
beta-hydroxybutyric acid; and a plurality of beta-hydroxybutyrate salts comprised of at least two of:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; or magnesium beta-hydroxybutyrate.
18. A kit for administering ketone bodies to a subject, comprising:
the beta-hydroxybutyrate mixed acid-salt composition of claim 1;
a container in which the composition is placed; and a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 1 g to about 50 g of beta-hydroxybutyrate compounds.
the beta-hydroxybutyrate mixed acid-salt composition of claim 1;
a container in which the composition is placed; and a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 1 g to about 50 g of beta-hydroxybutyrate compounds.
19. The kit of claim 18, wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, and keg.
20. The kit of claim 18 or 19, wherein the measuring device is selected from the group consisting of cup, scoop, syringe, dropper, spatula, spoon, and colonic irrigation device.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/272,145 | 2019-02-11 | ||
US16/272,145 US10736861B2 (en) | 2016-03-11 | 2019-02-11 | Mixed salt compositions for producing elevated and sustained ketosis |
US16/720,211 | 2019-12-19 | ||
US16/720,211 US11020362B2 (en) | 2016-03-11 | 2019-12-19 | Beta-hydroxybutyrate mixed salt compositions and methods of use |
PCT/US2020/016952 WO2020167571A1 (en) | 2019-02-11 | 2020-02-06 | Beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3129411A1 true CA3129411A1 (en) | 2020-08-20 |
Family
ID=72045290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3129411A Pending CA3129411A1 (en) | 2019-02-11 | 2020-02-06 | Beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3923918A4 (en) |
JP (2) | JP2022520560A (en) |
CN (1) | CN113660930A (en) |
AU (1) | AU2020221031A1 (en) |
CA (1) | CA3129411A1 (en) |
WO (1) | WO2020167571A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112262936A (en) * | 2020-10-22 | 2021-01-26 | 珠海麦得发生物科技股份有限公司 | Beverage containing 3-hydroxybutyric acid and preparation method and application thereof |
CN115251375A (en) * | 2022-07-11 | 2022-11-01 | 珠海麦得发生物科技股份有限公司 | (R) -3-hydroxybutyric acid ketonic product and preparation method thereof |
WO2024067626A1 (en) * | 2022-09-27 | 2024-04-04 | 南京纽邦生物科技有限公司 | Composite of acid and salt, and preparation method therefor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1585817B1 (en) * | 2002-02-20 | 2009-09-02 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
US8758740B2 (en) * | 2007-03-30 | 2014-06-24 | Earthus, Inc | Composition for promoting ketone body production |
US9211275B2 (en) * | 2008-01-04 | 2015-12-15 | Isis Innovation Ltd. | Ketone bodies and ketone body esters as blood lipid lowering agents |
EP2976073B1 (en) * | 2013-03-19 | 2019-08-28 | University Of South Florida | Compositions and methods for producing elevated and sustained ketosis |
US10292952B2 (en) * | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
CA3021784A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
US10588877B2 (en) * | 2016-07-21 | 2020-03-17 | Savind, Inc. | Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same |
US20180057846A1 (en) * | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
CA3053663C (en) * | 2017-04-12 | 2021-09-07 | Franco CAVALERI | Butyrate and beta-hydroxybutyrate compositions and methods of use thereof |
-
2020
- 2020-02-06 JP JP2021546766A patent/JP2022520560A/en active Pending
- 2020-02-06 WO PCT/US2020/016952 patent/WO2020167571A1/en unknown
- 2020-02-06 AU AU2020221031A patent/AU2020221031A1/en active Pending
- 2020-02-06 CN CN202080027567.1A patent/CN113660930A/en active Pending
- 2020-02-06 CA CA3129411A patent/CA3129411A1/en active Pending
- 2020-02-06 EP EP20755770.3A patent/EP3923918A4/en active Pending
-
2023
- 2023-10-02 JP JP2023171578A patent/JP2023166029A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113660930A (en) | 2021-11-16 |
JP2023166029A (en) | 2023-11-17 |
JP2022520560A (en) | 2022-03-31 |
WO2020167571A1 (en) | 2020-08-20 |
EP3923918A4 (en) | 2022-10-05 |
AU2020221031A1 (en) | 2021-09-02 |
EP3923918A1 (en) | 2021-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11020362B2 (en) | Beta-hydroxybutyrate mixed salt compositions and methods of use | |
US10973786B2 (en) | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions | |
US10292952B2 (en) | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis | |
US11690817B2 (en) | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use | |
US11896565B2 (en) | Beta-hydroxybutyrate mixed salt compositions and methods of use | |
US10596131B2 (en) | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use | |
US11185518B2 (en) | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer | |
CA3129411A1 (en) | Beta-hydroxybutyrate mixed salt-acid compositions and methods of use | |
JP2023166026A (en) | Non-racemic beta-hydroxybutyrate compounds, and compositions and kits enriched with r-enantiomer | |
CA3166226C (en) | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions | |
US11944598B2 (en) | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer | |
EP3923926A1 (en) | S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer | |
US20230346722A1 (en) | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the r-enantiomer and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20231025 |
|
EEER | Examination request |
Effective date: 20231025 |